AHA presents up-to-date statistics for cardiovascular disease
Jan 25, 2023
19.05 million deaths were estimated for CVD globally in 2020, representing an increase of 18.71% from 2010.
Strength of risk factors for stroke vary by age
Jan 20, 2023
The association of hypertension, heart disease and diabetes with stroke appears to be substantially reduced at older ages.
Nighttime hot spring bathing may decrease prevalence of HTN in older adults
Jan 05, 2023
An inverse relationship was seen between habitual nighttime hot spring bathing and a history of hypertension.
High coffee intake linked to CVD mortality in severe hypertension
Dec 21, 2022
“These findings may support the assertion that people with severe high blood pressure should avoid drinking excessive coffee,” a coauthor said in a statement.
Adding yoga to aerobic training lowers blood pressure
Dec 19, 2022
Blood pressure reduction was greater with 15 minutes a day of yoga, five times a week for three months, plus 30 minutes of aerobic training, compared with stretching control.
Intervention delivered via web-based platform ups BP control
Dec 07, 2022
The rate of BP control was significantly higher after 12 months of multicomponent intervention, with reduction in SBP of −10.1 mm Hg.
Team care with clinical decision support system beneficial for type 2 diabetes patients
Dec 06, 2022
Significantly greater decreases were seen in HbA1c levels, LDL-C levels and systolic blood pressure for team-based care with versus without a clinical decision support system.
Hypertension linked to increased risk for severe COVID-19
Nov 10, 2022
Elevated systolic blood pressure showed a dose-response relationship with severe COVID-19 for those taking antihypertensive meds.
Remote program beneficial for management of HTN, cholesterol
Nov 09, 2022
Significant reductions were seen in blood pressure and LDL-C at six and 12 months for patients enrolled in the remote program.
AHA: Baxdrostat studied in treatment-resistant hypertension
Nov 08, 2022
Dose-dependent reductions in systolic blood pressure were seen in the phase 2 dose-ranging study.